CytomX Therapeutics (CTMX) Net Cash Flow Growth (5y) (2019 - 2026)
CytomX Therapeutics (CTMX) Net Cash Flow Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - |
| 10 | CytomX Therapeutics | 603.61 Mn | 256.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.86% |
| Dec 31, 2025 | -27.71% |
| Sep 30, 2025 | 33.54% |
| Jun 30, 2025 | -60.43% |
| Mar 31, 2025 | 17.20% |
| Dec 31, 2024 | -16.06% |
| Sep 30, 2024 | -16.74% |
| Jun 30, 2024 | 16.78% |
| Mar 31, 2024 | 18.46% |
| Dec 31, 2023 | 6.18% |
| Sep 30, 2023 | -17.59% |
| Jun 30, 2023 | 16.30% |
| Mar 31, 2023 | -31.14% |
| Dec 31, 2022 | 23.94% |
| Sep 30, 2022 | -38.05% |
| Jun 30, 2022 | -16.90% |
| Mar 31, 2022 | -17.24% |
| Dec 31, 2021 | -21.84% |
| Sep 30, 2021 | -49.94% |
| Jun 30, 2021 | -67.85% |